Wet Age-related Macular Degeneration
📧 Sign up to get email alerts when something new happens for Wet Age-related Macular Degeneration.
Sign up freeTop drugs studied for this disease
-
EMA withdrawal · 2025-04-14EMA Application withdrawn: Skojoy (aflibercept) — Amgen Technology (Ireland) UC
EMA has withdrawn the marketing authorization application for Skojoy (aflibercept) submitted by Amgen Technology (Ireland) UC. The applicati…
-
EMA withdrawal · 2023-07-18EMA Application withdrawn: Susvimo (ranibizumab) — Roche Registration GmbH
The EMA indicates Susvimo (ranibizumab) application withdrawn by Roche Registration GmbH in the wet age-related macular degeneration program…
-
EMA withdrawal · 2022-12-02EMA Withdrawn: Macugen (pegaptanib) — PharmaSwiss Ceska Republika s.r.o
EMA has withdrawn Macugen (pegaptanib) for wet age-related macular degeneration.
-
CLINICAL_TRIALS withdrawal · 2022-08-10Clinical Trial Update: Brolucizumab vs. Aflibercept for Retinal Angiomatous Proliferation [Phase 4]
A Phase 4 trial comparing brolucizumab vs. aflibercept for wet macular degeneration has been withdrawn.
-
EMA withdrawal · 2022-05-24EMA Refused: Ipique (bevacizumab) — Rotterdam Biologics B.V.
The EMA refused the marketing authorization for Ipique (bevacizumab) by Rotterdam Biologics B.V. for wet age-related macular degeneration.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2017-02-15Clinical Trial Update: CANadian Study in Patients With Wet AMD, Evaluating the Efficacy and Safety of Switching From Intravitreal Aflibercept to RanIbizumab [Phase 4]
This clinical trial was withdrawn; it investigated switching from aflibercept (Eylea) to ranibizumab (Lucentis) for wet age-related macular …
-
CLINICAL_TRIALS withdrawal · 2016-03-31Clinical Trial Update: Safety and Efficacy Study of BCD-021 Compared to Lucentis® in Patients With Neovascular Wet Age-related Macular Degeneration [Phase 3]
A Phase 3 safety and efficacy trial comparing Biocad's BCD-021 to Lucentis for wet age-related macular degeneration has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2016-03-29Clinical Trial Update: HiPED - High Dose Lucentis for Persistent Pigment Epithelial Detachments in Age-related Macular Degeneration [Phase 2]
The Phase 2 HiPED trial evaluating high-dose ranibizumab (Lucentis) for persistent pigment epithelial detachments in age-related macular deg…
-
CLINICAL_TRIALS withdrawal · 2011-12-30Clinical Trial Update: Study to Evaluate the Safety and Effectiveness of IRay in Wet Age-related Macular Degeneration (AMD) Patients With Recurrent Leakage Secondary to Choroidal Neovascularisation (CNV) [NA]
A clinical trial evaluating IRay for wet age-related macular degeneration with recurrent leakage due to choroidal neovascularization has bee…